E uiga ile-kanesa / togafitiga / togafitiga-faʻafitauli / faʻamaʻi / merkel-sela / togafitiga
Togafitiga Togafitiga Togafitiga mo Merkel Cell Kanesa
Togafitiga faʻafomaʻi o suʻesuʻega suʻesuʻega e aʻafia ai tagata. O faʻataʻitaʻiga faʻafomaʻi i luga o lenei lisi e mo togafitiga o kanesa kanesa sela. O faʻataʻitaʻiga uma i luga o le lisi e lagolagoina e le NCI.
O faʻamatalaga taua a le NCI e uiga ile faʻataʻitaʻi ile falemaʻi o loʻo faʻamatalaina ai ituaiga ma vaega o faʻataʻitaʻiga ma faʻafefea ona faʻatinoina. Togafitiga faʻafomaʻi e vaʻai i ni auala fou e puipuia ai, iloa ai, pe togafitia ai faʻamaʻi. Atonu e te manaʻo e mafaufau e uiga i le auai i le faʻataʻitaʻiina o togafitiga. Talanoa i lau fomaʻi mo se fesoasoani i le filifiliga pe o se tasi e talafeagai mo oe.
Faʻataʻitaʻiga 1-25 o le 32 1 2 Le isi>
Pembrolizumab Faʻatusatusa i le Tulaga masani o Tausiga mataituina i le togafitia o tagata mamaʻi ma le maeʻa toe suʻesuʻeina Vaega I-III Merkel sela Kanesa
Lenei vaega III faʻataʻitaʻiga suʻesuʻega pe faʻafefea ona aoga le pembrolizumab pe a faʻatusatusa i le tulaga masani o le vaʻaia o tausiga i le togafitia o tagata mamaʻi i le tulaga I-III Merkel cell kanesa ua matua aveʻesea e le taotoga (toe maua). Immunotherapy ma monoclonal antibodies, pei o le pembrolizumab, ono fesoasoani i le tino o le tino puipuia osofaia le kanesa, ma ono faʻalavelave i le mafai o tumo sela e tupu ma salalau. Nofoaga: 286 nofoaga
Pembrolizumab ma pe leai Stereotactic Tino Radiation Togafitiga i le togafitia o tagata mamaʻi ma Advanced po o Metastatic Merkel Cell Kanesa
O lenei faʻataʻitaʻiga laasaga II faʻataʻitaʻiga suʻesuʻega pe faʻafefea ona lelei le pandrolizumab ma le leai o le stereotactic body radiation therapy e galue ai i le togafitia o tagata mamaʻi ma le kanesa sela o Merkel ua salalau atu i isi nofoaga i le tino. Immunotherapy ma monoclonal antibodies, pei o le pembrolizumab, ono fesoasoani i le tino o le tino puipuia osofaia le kanesa, ma ono faʻalavelave i le mafai o tumo sela e tupu ma salalau. O le Stereotactic body radiation therapy e faʻaaoga ai meafaigaluega faʻapitoa e faʻatulagaina ai se tagata maʻi ma tuʻuina atu le radiation i tumors ma le maualuga atoatoa. Lenei metotia mafai fasiotia fasiotia sela sela ma le itiiti ifo tui i luga o se puʻupuʻu vaitaimi ma mafua ai laʻititi faʻaleagaina o masani aano. Le mauaina o le pembrolizumab ma le stereotactic body radiation therapy atonu e sili atu le aoga ile togafitia o tagata mamaʻi ile Merkel cell cancer.
Nofoaga: 246 nofoaga
Suesuega Immuno-togafitiga Suesuega e suʻesuʻe ai le Saogalēmū ma le aoga o Nivolumab, ma Nivolumab Combination Therapy i Virus-fesoʻotaʻiga Tumors
O le mafuaʻaga o lenei suʻesuʻega e suʻesuʻe ai le saogalemu ma le aoga o le nivolumab, ma le nivolumab tuufaatasi togafitiga, e togafitia ai tagata mamaʻi o loʻo i ai siama e fesoʻotaʻi ma siama. O nisi siama ua lauiloa e faia se sao i tumo fausiaina ma le tuputupu ae. O lenei suʻesuʻega o le a suʻesuʻeina ai aʻafiaga o vailaʻau suʻesuʻe, i tagata mamaʻi o loʻo i ai ituaiga ituaiga o tuma nei - ituaiga kanesa - Merkel Cell Cancer - Kanesa kanesa-E le toe lesitalaina lenei ituaiga tuma - Vaʻaiga ma kanesa feula-E le toe lesitalaina lenei ituaiga tuma - Kanesa kanesa - E le toe lesitalaina lenei ituaiga tuma - Ao ma le Kanesa Kanesa - Le toe lesitalaina nei ituaiga tuma
Nofoaga: 10 nofoaga
Lenei Suʻesuʻega Iloilo le KRT-232, o le Novel Oral Small Molecule Inhibitor o le MDM2, mo le togafitia o tagata mamaʻi ma (p53WT) Merkel Cell Carcinoma O e ua le mafai Anti-PD-1 / PD-L1 Immunotherapy
O lenei suʻesuʻega e iloilo ai le KRT-232, o se tala tuʻi laititi mole faʻatamaina o le MDM2, mo le togafitia o tagata mamaʻi ma Merkel Cell Carcinoma (MCC) ua le manuia togafitiga ma le sili atu tasi anti-PD-1 poʻo anti-PD-L1 immunotherapy. O le taofiofia ole MDM2 ose tala fou lea o gaioiga i le MCC. O lenei suʻesuʻega o le Vaega 2, Open-Label, Nofofua-Lima Suʻesuʻega o le KRT-232 i Tagata mamaʻi ma le p53 Wild-Type (p53WT) Merkel Cell Carcinoma
Nofoaga: 11 nofoaga
Adjuvant Avelumab i le Merkel Cell Kanesa
O lenei randomized phase III faʻataʻitaʻiga suʻesuʻega pe faʻafefea ona aoga avelumab i le togafitia o tagata mamaʻi ma Merkel cell kanesa ua sosolo atu i le lymph nodes ma sa faia se taotoga ma pe leai radiation togafitiga. Monoclonal antibodies, pei o le avelumab, e ono faʻaosofia ai le puipuiga o le tino ma faʻalavelave ai i le mafai o sela tuma e tutupu ma sosolo.
Nofoaga: 10 nofoaga
QUILT-3.055: O se Suesueina o le ALT-803 i le Tuʻufaʻatasia ma le PD-1 / PD-L1 Checkpoint Inhibitor i tagata mamaʻi ma kanesa maualuga.
Lenei o le Vaega IIb, tasi-lima, multicohort, tatala-igoa multicenter suʻesuʻega o le ALT-803 faʻatasi ai ma le FDA-faʻamaonia PD-1 / PD-L1 siaki siaki taofi i tagata mamaʻi ma alualu i luma kanesa ua alualu i luma mulimuli ane i le amataga tali i togafitiga ma le PD-1 / PD-L1 siaki auala e taofi ai le auala. O gasegase uma o le a mauaina le tuʻufaʻatasiga togafitiga o PD-1 / PD-L1 siaki siaki faʻatasi ai ma le ALT-803 e oʻo atu i le 16 taʻamilosaga. Taamilosaga taʻitasi e ono vaiaso le umi. Uma gasegase o le a mauaina ALT-803 tasi i le 3 vaiaso. O tagata gasegase o le a mauaina foi le tutusa siaki siaki na latou mauaina i le taimi o latou togafitiga muamua. Radiologic iloiloina o le a tupu i le faaiuga o taʻamilosaga taʻamilosaga taʻitasi. Togafitiga o le a faʻaauau pea e oʻo atu i le 2 tausaga, pe seʻi vagana ua maua e le tagata maʻi faʻamaonia alualu i luma faʻamaʻi poʻo le taliaina oona, faʻateʻaina maliega, pe afai e lagona e le Tagata suʻesuʻe ua le o toe i le lelei a le tagata maʻi ona faʻaauau togafitiga. Tagata mamaʻi o le a mulimulitaʻia mo faʻamaʻi alualu i luma, post-therapies, ma le ola e ala i le 24 masina talu ai pulega o le muamua fualaʻau o suʻesuʻega vailaʻau.
Nofoaga: 9 nofoaga
O se suʻesuʻega o le NKTR-262 i le tuʻufaʻatasia ma le NKTR-214 ma le NKTR-214 Plus Nivolumab i tagata mamaʻi ma faʻaletonu i luga ole laʻau tutoʻi.
Tagata mamaʻi o le a mauaina intra-tumoral (IT) NKTR-262 i le 3-vaiaso togafitiga taʻamilosaga. I le taimi o le vaega 1 fualaʻau faʻateleina vaega o le faʻamasinoga, NKTR-262 o le a tuʻufaʻatasia ma faʻatonutonuina faiga o bempegaldesleukin. A maeʻa ona fuafuaina le tuʻufaʻatasia Vaega fautuaina 2 (RP2D) o le NKTR-262, i le va o le 6 ma le 12 tagata mamaʻi e mafai ona lesitalaina i le RP2D e faʻamalamalama atili ai le saogalemu ma le faʻapalepale faʻamatalaga o le tuʻufaʻatasia o le NKTR 262 ma le bempegaldesleukin (faʻalua) poʻo le NKTR 262 faʻaopoopo. bempegaldesleukin faatasi ai ma le nivolumab (tolu tolu) i Cohorts A ma le B, faʻatulagaina. I le vaega 2 fualaʻau faʻalauteleina vaega, tagata gasegase o le a togafitia i le faaluaina poʻo le tolu tolu i le toe faʻafouina / refactory faʻatulagaina ma muamua laina o togafitiga.
Nofoaga: 14 nofoaga
O se Suesuega o le INCMGA00012 i le Metastatic Merkel Cell Carcinoma (POD1UM-201)
O le mafuaʻaga o lenei suʻesuʻega o le iloiloina o le falemaʻi gaioiga ma le saogalemu o INCMGA00012 i tagata auai ma alualu i luma / metastatic Merkel sela kanesa (MCC).
Nofoaga: 8 nofoaga
PEN-221 i le Somatostatin Receptor 2 Faʻamatalaina o le maualalo kanesa aofia ai Neuroendocrine ma Laʻitiiti sela sela mama
Maliega PEN-221-001 o se tatala-igoa, multicenter Vaega 1 / 2a suʻesuʻe iloilo PEN-221 i tagata mamaʻi ma SSTR2 faʻaalia alualu i luma gastroenteropancreatic (GEP) poʻo mama po thymus poʻo isi neuroendocrine tumors poʻo laʻititi sela kanesa kanesa po o le tele sela sela neuroendocrine o le māmā.
Nofoaga: 7 nofoaga
O le Vasega 1/2 Suʻesuʻega o le faia o tui Faʻatasi ai ma le Tremelimumab ma le IV Durvalumab Plus PolyICLC i mataupu e le mafai ona maua, mafai ona fuaina, ma faʻafesoʻotaʻiga e le mafai ona mauaina.
Lenei o se matala-igoa, multicenter Vaega 1/2 suʻesuʻega o le CTLA-4 vailaʻau, tremelimumab, ma le PD-L1 vailaʻau, durvalumab (MEDI4736), i le tuʻufaʻatasia ma le patu microen environment (TME) modulator polyICLC, o le TLR3 agonist, i mataupu ma sili atu, fuaina, biopsy-maua kanesa.
Nofoaga: 6 nofoaga
Intratumoral AST-008 Tuʻufaʻatasia ma Pembrolizumab i Tagata Maʻi Ma Tumua Maea Tumors
Lenei o le vaega 1b / 2, tatala-igoa, multicenter tofotofoga fuafuaina e iloilo le saogalemu, faʻapalepaleina, vailaʻau, vailaʻau ma vailaʻau muamua aoga o intratumoral AST-008 tui naʻo ma faʻatasi ma le intravenous pembrolizumab i tagata mamaʻi ma maualuluga tumors tuma. Vaega 1b o lenei faʻataʻitaʻiga o le 3 + 3 fualaʻau faʻateleina suʻesuʻega iloiloina faʻateleina poʻo le ogatotonu fualaʻau maualuga o le AST-008 na tuʻuina atu ma le faʻatulagaina fuala o le pembrolizumab. Vaega 2 o se faʻalautelega kulupu e toe suʻesuʻe AST-008 na tuʻufaʻatasia ma le pembrolizumab i se tagata faʻapitoa e maua ai se faʻamuamua fua o le aoga i tagata mamaʻi na mauaina muamua ae le tali atu i le anti-PD-1 poʻo le anti-PD-L1 antibody togafitiga.
Nofoaga: 7 nofoaga
Faʻataʻitaʻiga o Iniseti Intratumoral o le TTI-621 i mataupu e faʻafouina ma toe faʻamalosia Tumors mautu ma Mycosis Fungoides
Lenei o le multicenter, matala-igoa, vaega 1 suʻesuʻega faʻatautaia e suʻesuʻe tuiina intratumoral o TTI-621 i mataupu na toe faʻafouina ma faʻafaigofie faʻasolo maua gofie tuma paʻu poʻo mycosis fungoides. O le a faia le suʻesuʻega i ni vaega eseʻese se lua. Vaega 1 o le Faʻateleina o le Dose phase ma le Vaega 2 o le Dose Expansion phase. O le mafuaʻaga o lenei suʻesuʻega o le faʻailoaina o le saogalemu talaaga o le TTI-621 ma ia faʻamautinoa le tofo lelei ma le kilivaina o TTI-621. I se faʻaopopoga, o le saogalemu ma antitumor gaioiga o TTI-621 o le a iloiloina faʻatasi ma isi anti-kanesa sooupu poʻo radiation.
Nofoaga: 5 nofoaga
Suesueina o le RP1 Monotherapy ma le RP1 i le Tuufaatasi ma Nivolumab
RPL-001-16 o le Vaega 1/2, matala igoa, inumaga faʻateleina ma faʻalauteleina falemaʻi suʻesuʻega o le RP1 na o ia ma faʻatasi ma le nivolumab i tagata matutua mataupu ma alualu i luma ma / pe faʻamalosi tino tumors, e fuafua ai le maualuga faʻatagaina fualaʻau (MTD) ma fautuaina le Vaega 2 fualaʻau (RP2D), faʻapea foi ma le iloiloina muamua aoga.
Nofoaga: 6 nofoaga
Talimogene Laherparepvec ma poʻo aunoa ma le Hypofractionated Radiation Therapy i le togafitia o tagata mamaʻi ma Metastatic Melanoma, Merkel Cell Carcinoma, poʻo Isi Tumors Mautu
O lenei faʻataʻitaʻiga laʻasaga II faʻataʻitaʻiga suʻesuʻeina le itu aʻafiaga o talimogene laherparepvec ma ia vaʻaia pe faʻafefea ona aoga ma pe leai hypofractionated radiation togafitiga i le togafitia o tagata mamaʻi ma le melanoma paʻu, Merkel cell carcinoma, poʻo isi faʻamaonia tumors ua salalau i nofoaga le talafeagai mo toʻesea taotoga . O vailaʻau o loʻo faʻaaogaina i le vailaʻau puipuia, pei o talimogene laherparepvec, e ono faʻaosofia ai le tino o le tino e teteʻe atu i sela tuma. Ole togafiti ole faʻamalositino ile faʻamalositino e maua ai le maualuga ole paʻu ole faʻamalositino ile taimi puʻupuʻu ma ono fasiotia ai le tele o sela tuma male laʻititi o aʻafiaga. E leʻo iloa pe a fai o le talimogene laherparepvec ma le leai o le hypofractionated radiation therapy o le a sili atu ona lelei i le togafitia o tagata mamaʻi ma le cutane melanoma, Merkel cell carcinoma, poʻo le tuma faʻamaonia.
Nofoaga: 3 nofoaga
FT500 e pei o Monotherapy ma i le tuʻufaʻatasia ma le puipuia o le siakiina o siaki puipuia i mataupu o loʻo i ai alualu i luma tuma
FT500 o se i fafo atu o le fata, iPSC-maua NK sela oloa e mafai ona aliaʻe le natura ma fetuutuunai puipuiga, ma ei ai le gafatia e foʻia ai le tele o auala o le puipuia siaki siaki (ICI) teteʻe. O faʻamatalaga tuʻuina mai na saunia ai faʻamaoniga malosi e lagolagoina ai le suʻesuʻeina o le falemaʻi o le FT500 e pei o le monotherapy ma le tuʻufaʻatasia ma le ICI i mataupu o loʻo i ai ni tuma tetele.
Nofoaga: 3 nofoaga
Tacrolimus, Nivolumab, ma Ipilimumab i le togafitia o Fatugaʻi Fesuiaʻiga Tagata Mauaina ma Filifilia Unresectable po Metastatic Cancers
O lenei vaega ou te suʻesuʻeina suʻesuʻega pe o le a le lelei o le tacrolimus, nivolumab, ma le ipilimumab e galue ai i le togafitia o tagata e tipiina fatugaʻo ma kanesa e le mafai ona aveʻesea e se taotoga (le mafai ona tatalaina) pe ua salalau atu foi i isi nofoaga i le tino (metastatic). Tacrolimus ono taofi le tuputupu aʻe o sela tuma i le polokaina o nisi o enzymes manaʻomia mo sela tuputupu aʻe. Immunotherapy ma monoclonal antibodies, pei o le nivolumab ma ipilimumab, e ono fesoasoani i le tino o le tino i osofaʻiga o le kanesa, ma ono faʻalavelave ai ile mafai o sela tuma e tutupu ma sosolo. O le tuʻuina atu ole tacrolimus, nivolumab, ma le ipilimumab e mafai ona sili atu lona aoga ile togafitia o tagata ua maua i le kanesa ile kanesa pe a faʻatusatusa ile chemotherapy, taotoga, radiation therapy, poʻo togafitiga faʻapitoa.
Nofoaga: 2 nofoaga
Nivolumab ma Ipilimumab ma poʻo aunoa ma le Stereotactic Tino Radiation Togafitiga i le togafitia o tagata gasegase ma toe tupu poʻo tulaga IV Merkel sela kanesa
Lenei randomized vaega II faʻataʻitaʻiga suʻesuʻega pe o le a le lelei o le nivolumab ma le ipilimumab ma poʻo le leai foi o le stereotactic body radiation therapy galue i le togafitia o tagata mamaʻi ma Merkel cell kanesa ua toe foʻi mai pe o le tulaga IV. Immunotherapy ma monoclonal antibodies, pei o le nivolumab ma ipilimumab, e ono fesoasoani i le tino o le tino i osofaʻiga o le kanesa, ma ono faʻalavelave ai ile mafai o sela tuma e tutupu ma sosolo. O le Stereotactic body radiation therapy e faʻaaoga ai meafaigaluega faʻapitoa e faʻatulagaina ai se tagata maʻi ma tuʻuina atu le radiation i tumors ma le maualuga atoatoa. Lenei metotia mafai fasiotia fasiotia sela sela ma le itiiti ifo tui i luga o se puʻupuʻu vaitaimi ma mafua ai laʻititi faʻaleagaina o masani aano. Le mauaina o le nivolumab ma le ipilimumab ma le leai o le stereotactic body radiation therapy atonu e sili atu le aoga i le togafitia o tagata mamaʻi i le Merkel cell cancer.
Nofoaga: 2 nofoaga
Pembrolizumab ma Radiation Therapy mo le togafitiga o Metastatic Merkel Cell Carcinoma
Lenei vaega II suʻesuʻega suʻesuʻeina le itu aʻafiaga ma pe faʻafefea ona aoga le bekrolizumab ma le radiation therapy i le togafitia o tagata mamaʻi ma Merkel cell carcinoma ua salalau atu i isi nofoaga i le tino (metastatic). Immunotherapy ma monoclonal antibodies, pei o le pembrolizumab, ono fesoasoani i le tino o le tino puipuia osofaia le kanesa, ma ono faʻalavelave i le mafai o tumo sela e tupu ma salalau. Radiation togafitiga faʻaaogaina malosiaga maualuga x-ave e fasiotia tumo sela ma tuʻumomuina patu. O le tuʻuina o le pembrolizumab ma le radiation therapy e ono faʻatele ai le penefiti o le pembrolizumab.
Nofoaga: Stanford Cancer Institute Palo Alto, Palo Alto, Kalefonia
O se suʻesuʻega o le LY3434172, o le PD-1 ma le PD-L1 Bispecific Antibody, i le Advanced Cancer
O le autu mafuaʻaga o lenei suʻesuʻega o le iloiloina o le saogalemu ma le faʻapalepaleina o le suʻesuʻega fualaʻau LY3434172, o le PD-1 / PD-L1 bispecific antibody, i sui auai ma alualu i luma tuma.
Nofoaga: MD Anderson Cancer Center, Houston, Texas
Cell Therapy (Tumor Infiltrating Lymphocytes) mo le togafitia o le faʻalauteleina o le tulaga, metastatic, poʻo le toe tupu solo.
Lenei vaega II suʻesuʻega suʻesuʻe pe faʻafefea ona aoga sela togafitiga (ma tumo infiltrating lymphocytes) galue mo le togafitia o mautu kanesa ua salalau atu i latalata aano poʻo lymph nodes (faʻalapotopotoga maualuga), ua salalau atu i isi vaega o le tino (metastatic), pe ua sau i tua (toe tupu). O lenei faʻataʻitaʻiga e aofia ai le aveina o sela ua taʻua o lymphocytes (o se ituaiga sela paʻepaʻe) mai tuma o tagata mamaʻi, faʻatupuina i latou i le potu suesue i ni numera se tele, ona toe avatu ai lea o sela i le tagata maʻi. O nei sela ua taʻua o le tumo infiltrating lymphocytes ma o le togafitiga e taʻua o le cell therapy. O le tuʻuina atu o vailaʻau o le chemotherapy ae leʻi mafai e sela ona taofia le puipuia o le tino e faʻaleleia atili ai avanoa e mafai ai ona ola le tino i le tino. Le mauaina o le aldesleukin pe a maeʻa le faʻatautaia o sela e mafai ona fesoasoani i le fetauaʻi o sela faʻaola tumau umi.
Nofoaga: Iunivesite o Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Nivolumab ma Radiation Therapy poʻo Ipilimumab o Adjuvant Therapy i le togafitia o tagata mamaʻi ma Merkel Cell Kanesa
O lenei vaega ou te suʻesuʻeina suʻesuʻega o aʻafiaga ma le lelei o le galue o le nivolumab pe a tuʻuina faʻatasi ma le radiation therapy poʻo le ipilimumab o le adjuvant therapy i le togafitia o tagata mamaʻi ua maua i le kanesa o Merkel. Immunotherapy ma monoclonal antibodies, pei o le nivolumab ma ipilimumab, e ono fesoasoani i le tino o le tino i osofaʻiga o le kanesa, ma ono faʻalavelave ai ile mafai o sela tuma e tutupu ma sosolo. Radiation togafitiga faʻaaogaina malosiaga maualuga x-ave, gamma ave, neutonu, proton po o isi punaoa e fasioti tuma sela ma tuʻumomuina patu. O le faia o le nivolumab ma le radiation therapy poʻo le ipilimumab pe a uma le taotoga e ono fasiotia ai soʻo se totoga na totoe.
Nofoaga: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Pembrolizumab (MK-3475) o le First-line Therapy mo Advanced Merkel Cell Carcinoma (MK-3475-913)
Lenei o le tasi-lima, matala-igoa, multicenter, aoga, ma le saogalemu suʻesuʻega o le pembrolizumab i tagata matutua ma tamaiti auai ma muamua le togafitia Merkel Cell Carcinoma (MCC). O le autu o le faʻamasinoga o le iloiloina o le fua faʻatatau tali, e pei ona iloiloina e le tutoʻatasi tutoʻatasi iloiloga mo Response Evaluation Criteria i Solid Tumors lomiga 1.1 (RECIST 1.1) suia ina ia mulimulitaʻi i le maualuga o le 10 faʻataunuʻuina lesions ma le maualuga o le 5 faʻatamaʻiʻona i le okeni, mulimuli i le faʻatautaiga o le pembrolizumab.
Nofoaga: Laura ma Isaac Perlmutter Kanesa Center i NYU Langone, Niu Ioka, Niu Ioka
Gene-Modified Immune Cells (FH-MCVA2TCR) i le togafitia o tagata mamaʻi ma Metastatic pe le mafai ona tatalaina Merkel Cell Kanesa
Lenei vaega I / II suʻesuʻega suesueina le itu aafiaga o sela-fesuiaʻi sela puipuia (FH-MCVA2TCR) ma ia iloa pe o le a le lelei latou te galue ai i le togafitia o tagata mamaʻi ma Merkel sela kanesa ua salalau atu i isi vaega o le tino (metastatic) pe e le mafai aveese ile taotoga (le mafai ona tatalaina). Faʻapipiʻiina se kenera na faia i totonu o fale suesue i sela puipuia e mafai ona faʻaleleia atili ai le malosi o le tino e teteʻe atu ai i le kanesa o le sela Merkel.
Nofoaga: Fred Hutch / Iunivesite o Washington Cancer Consortium, Seattle, Uosigitone
O se Saogalēmū ma faʻapalepale Suesuega o INCAGN02390 i le Select Advanced Malignancies
O le mafuaʻaga o lenei suʻesuʻega o le faʻamautinoaina lea o le saogalemu, faʻapalepaleina, ma le muamua aoga o INCAGN02390 i sui o loʻo iai ma filifiliga leaga ua leva.
Nofoaga: Hackensack Iunivesite Falemai Nofoaga, Hackensack, New Jersey
Abexinostat ma Pembrolizumab i le togafitia o gasegase ma MSI-Maualuga i le lotoifale poʻo Metastatic maʻi Tumors.
O lenei vaega ou te suʻesuʻeina suʻesuʻega le sili ona lelei fualaʻau ma aʻafiaga o le abexinostat ma faʻafefea ona aoga ma le tuʻuina atu faʻatasi ma le pembrolizumab i le togafitia o tagata mamaʻi ma le microsatellite instability (MSI) maʻi tuma na salalau atu i latalata i aano o le tino poʻo lymph nodes (faʻalauteleina alualu i luma) poʻo isi nofoaga i le tino (metastatic). Abexinostat ono taofi le tuputupu aʻe o sela tuma i le polokaina o nisi o enzymes e manaʻomia mo le tuputupu aʻe sela. Immunotherapy ma monoclonal antibodies, pei o le pembrolizumab, ono fesoasoani i le tino o le tino puipuia osofaia le kanesa, ma ono faʻalavelave i le mafai o tumo sela e tupu ma salalau. Le maua o le abexinostat ma le pembrolizumab atonu e sili atu le lelei ile togafitia o tagata mamaʻi e iai ona tuma.
Nofoaga: UCSF Medical Center-Mount Siona, San Francisco, Kalefonia
1 2 sosoo ai>
